Europe Hemophilia Management Market Research Report – Segmented By Type, Drug & By Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) – Analysis on Size, Share, Trends, Growth, Forecasts (2024 to 2029)

Updated On: June, 2024
ID: 272
Pages: 141

Europe Hemophilia Management Market Size (2022 to 2027)

As per our report, the size of the Europe Hemophilia Management Market was worth USD 1299.71 million in 2022 and estimated to be growing at a CAGR of 1.54%, to reach USD 1402.92 million by 2027.

Various factors that influence the growth of the European hemophilia management market include the increasing prevalence of hemophilia disorder, well-developed healthcare infrastructure, favorable health insurance, and supportive healthcare awareness programs to educate the population. The most common type of hemophilia reported is hemophilia A, which is due to the deficiency of coagulation factor VIII, the prevalence in the UK is recorded between 1:5,000 and 1:10,000 men. While Hemophilia B, which is due to the deficiency of factor IX, is less common with a recorded prevalence between 1:35,000 and 1:50,000 men. Doctors estimate that hemophilia C affects around one in a million people. Still, it is much more common in specific populations, including the Ashkenazi Jewish community, affecting one in 450 people. Furthermore, the disease is mainly prevalent in the geriatric population, with a mortality rate of around 22% if left untreated. All this data suggests the demand for hemophilia management in Europe during the forecast period.

Untreated hemophilia can be a life-threatening disorder, which can lead to complications. However, these bleeding disorders can be treated with plasma-derived clotting factors, recombinant clotting derivatives, antifibrinolytics, fibrin sealants, etc. In addition, other factors like the rising healthcare expenditures, research and development activities associated with hemophilia, a growing trend in adopting technologically advanced treatment options, and the expansion of pharmaceutical companies into recombinant products resulting in the launch of new products will have a positive influence on the market.

However, factors such as higher prices associated with hemophilia treatment options, stringent FDA regulations regarding the drug approval process and absence of any permanent cure for hemophilia, and the presence of counterfeit drugs are hampering the growth of the European hemophilia management market over the forecast period.

This research report on the European hemophilia management market has been segmented and sub-segmented into the following categories:

By Type:

  • Hemophilia A
  • Hemophilia B

By Drug:

  • Octocogalfa
  • Nonacogalfa
  • Desmopressin
  • Other Drugs

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

The regional market in the United Kingdom holds the largest market share in the European hemophilia management market. This market growth can be attributed to the presence of more market players and well-developed healthcare institutions, increased prevalence of hemophilia, high disposable income, adequate reimbursement policies, early availability, and adoption of the latest medications. As a result, in 2020, the number of people in the UK diagnosed with a blood disorder has increased, with over 8,509 diagnosed with hemophilia.

The hemophilia management market in France and Germany are expected to witness significant growth over the forecasted period owing to the presence of better medical facilities, sufficient funding for clinical trials for research and development, increasing use of technologically advanced products for the treatment of hemophilia, and growing prevalence of this disease in the regions. A recent French study provided information that over 3,435 hemophiliacs showed a prevalence of around 6.25% for the overall population. Meanwhile, the prevalence of treated hemophilia A in Germany was recorded at over 3.58 cases per 100,000 persons, with a cumulative incidence of 0.34/100,000. And the prevalence of hemophilia B was reported to be around 0.62/100,000. Healthcare professionals focus on R&D-related studies to innovate new and better products with lesser side effects.


Companies playing a promising role in the European hemophilia management market profiled in this report are Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma, and Swedish Orphan Biovitrum AB.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample